Zacks Research Upgrades Cyclerion Therapeutics (NASDAQ:KRSA) to “Hold”

Cyclerion Therapeutics (NASDAQ:KRSA) was upgraded by analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Cyclerion Therapeutics Stock Down 100.0%

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.